Retifanlimab not checked

Incyte Corporation · INCMGA0012 · MGA012

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 1 trial completes
Trials
5 active
24 in total · 11 in the EU
Targets
 

What this is

How it works
Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Receptor-1 Blocking Antibody FDA class
Tested for
Solid Tumors
Main trialPhase 1
“This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.”In the company’s words, NCT06179160 on ClinicalTrials.gov
Other names
INCMGA0012 · MGA012 · INCMGA00012.

Other drugs for Solid Tumors

All 2438 drugs for Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials24

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Jan 2027 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 3Completed 15 Dec 2023 Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Phase 3Completed 15 Apr 2024 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Phase 2Completed 8 Jun 2020 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Phase 2Completed 15 Apr 2021 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Phase 2Completed 21 Jan 2022 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Phase 2Terminated 29 Jan 2024 An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
Phase 2Terminated 11 Apr 2024 The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Phase 2Withdrawn 20 Apr 2024 INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2Completed 14 Mar 2025 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2Completed 29 May 2026 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Phase 1/2Terminated 17 Dec 2021 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Phase 1/2Completed 25 Aug 2025 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Phase 1/2Terminated 29 Jul 2026 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Phase 1Completed 14 Dec 2021 A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
Phase 1Completed 21 Nov 2022 INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Phase 1Completed 22 Jan 2024 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1Completed 22 May 2024 A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Phase 1Terminated 19 Sep 2024 Study of INCA 0186 in Subjects With Advanced Solid Tumors
Phase 1Terminated 10 Sep 2025 A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Phase 2Authorised not given PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma
Phase 2Authorised not given Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study
Phase 2Authorised not given TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SARCOMAS
Phase 2Authorised not given Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Retifanlimab

Following is part of Solo: you see every change to Retifanlimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in